Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.

Early systemic sclerosis Epidemiology Incidence and progression Interstitial lung disease Prevalence Systemic sclerosis

Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
10 2021
Historique:
received: 30 09 2020
revised: 08 04 2021
accepted: 27 07 2021
pubmed: 18 8 2021
medline: 29 10 2021
entrez: 17 8 2021
Statut: ppublish

Résumé

The epidemiology of interstitial lung disease (ILD) in systemic sclerosis (SSc) in Belgium is unknown. In literature, its prevalence varies between 19% and 52% in limited/diffuse cutaneous SSc (LcSSc/DcSSc). However, its prevalence in "early" SSc (pre-clinically overt SSc without [yet] skin involvement), nor its incidence rate in SSc (LcSSc/DcSSc/"early" SSc) has ever been described. Against this background, we aimed to determine the prevalence/incidence (rate) and progression of ILD in SSc. 12-year follow-up data of consecutive SSc patients, included in two Flemish cohorts (University Hospitals Ghent and Leuven), were retrospectively analysed. ILD was classified according to the simplified Goh algorithm. Progression of ILD was defined as a relative decline of FVC ≥10%, a combined relative decline of FVC 5-10% and DLCO ≥15%, or as an increase in HRCT extent. 722 patients (60% LcSSc/ 20% DcSSc/ 20% "early" SSc, median (IQR) follow-up 39 [12-80] months) had baseline HRCT. 243 were rated to have ILD at baseline and 39 during follow-up (prevalence of 34%/ incidence rate of 20.3/1000PY, 95%CI:14.5-27.8). Amongst those with baseline ILD, 60% had lung functional progression at five years of follow-up. In the "early" SSc subgroup, eight patients were rated to have ILD at baseline and three during follow-up (prevalence of 6%/ incidence rate of 5.8/1000 PY, 95%CI:1.2-17.0). Both LcSSc and DcSSc patients should be monitored for ILD evolution. The low prevalence and incidence of ILD in the "early" SSc subgroup may instruct future decisions on the construction of uniform patient follow-up pathways in "early" SSc.

Identifiants

pubmed: 34403812
pii: S0049-0172(21)00149-9
doi: 10.1016/j.semarthrit.2021.07.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

969-976

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Els Vandecasteele (E)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Cardiology, Ghent University Hospital, Ghent, Belgium. Electronic address: els.vandecasteele@ugent.be.

Karin Melsens (K)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. Electronic address: karin.melsens@ugent.be.

Amber Vanhaecke (A)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. Electronic address: amber.vanhaecke@ugent.be.

Daniel Blockmans (D)

Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium. Electronic address: daniel.blockmans@uzleuven.be.

Carolien Bonroy (C)

Department of Diagnostic Sciences, Ghent University, Ghent, Belgium; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium. Electronic address: carolien.bonroy@uzgent.be.

Charlotte Carton (C)

Department of Internal Medicine, Ghent University, Ghent, Belgium. Electronic address: charlotte.carton@ugent.be.

Ellen Deschepper (E)

Biostatistics Unit, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. Electronic address: ellen.deschepper@ugent.be.

Filip De Keyser (F)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium and praktijk10A, Maldegem, Belgium. Electronic address: filip.dekeyser@praktijk10a.be.

Frédéric Houssiau (F)

Department of Rheumatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Louvain-la-Neuve, Belgium. Electronic address: frederic.houssiau@uclouvain.be.

Yves Piette (Y)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium. Electronic address: yves.piette@azsintjan.be.

Marie Vanthuyne (M)

Department of Rheumatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Louvain-la-Neuve, Belgium. Electronic address: marie.vanthuyne@uclouvain.be.

Koen Verbeke (K)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. Electronic address: koenverbeke100@gmail.com.

Rene Westhovens (R)

Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven, Leuven, Belgium. Electronic address: rene.westhovens@uzleuven.be.

Wim A Wuyts (WA)

Department of Respiratory Medicine, Unit for interstitial lung diseases, University Hospitals Leuven, Leuven, Belgium. Electronic address: wim.wuyts@uzleuven.be.

Ellen De Langhe (E)

Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium. Electronic address: ellen.delanghe@uzleuven.be.

Guy Brusselle (G)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Departments of Epidemiology and Respiratory Medicine, ErasmusMC, Rotterdam, the Netherlands. Electronic address: guy.brusselle@uzgent.be.

Vanessa Smith (V)

Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium. Electronic address: vanessa.smith@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH